Abstract
The circadian rhythm is a major environmental regulator of plants and animal physiology. The alternation of days and nights is translated at the cell and tissue level thanks to a molecular machinery, called the circadian clock. This clock controls in particular numerous endocrine functions, and its imbalances can have serious consequences on homeostasis. This is particularly true for the development of endocrine-related cancers, like breast, ovarian and prostate cancer. Circadian rhythm disorder (CRD) not only affects key hormone levels (including oestrogen, melatonin, insulin, glucagon, cortisol) but also favours a pro-inflammatory and immunosuppressive phenotype in the tumour microenvironment. This particular aspect is conducive to epithelial-mesenchymal transition (EMT) of solid epithelial tumours and cancer cell dissemination. It also favours resistance to chemo- and immunotherapy. Here, we discuss the current knowledge on this crosstalk between CRD, EMT and the immune microenvironment in endocrine-related cancers and its consequences for the development of efficient therapies.
Original language | English |
---|---|
Pages (from-to) | R67–R80 |
Number of pages | 14 |
Journal | Endocrine-Related Cancer |
Volume | 28 |
Issue number | 2 |
DOIs | |
Publication status | Published - 28 Feb 2021 |
Bibliographical note
Funding Information:This work was funded by Inserm, University Paris Saclay, INRAE, Association Institut de Cancérologie et d'Immunogénétique (ICIG), Vaincre le Cancer-NRB, Fond Avenir MASFIP, and GEFLUC - Les Entreprises contre le cancer.
Publisher Copyright:
© 2021 Society for Endocrinology Published by Bioscientifica Ltd. Printed in Great Britain
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.